Asia Leads in Adoptive Cell Therapy Trials, Driving Global Growth
Did you know that the Asia Pacific (APAC) region is significantly advancing adoptive cell therapy clinical trials compared to Europe and North America? This revelation was made by Scotty Chung-Siu from GlobalData at the Annual Outsourcing in Clinical Trials conference.
According to Chung-Siu, APAC conducts twelve times more single-country adoptive cell therapy trials than Europe, with 1,023 trials in APAC and 476 in North America. Adoptive cell therapies, which empower a patient's immune system to combat illnesses using engineered cells, come in various forms such as TIL, NK, and T cell immunotherapies, including the widely acclaimed CAR-T cell therapies.
Well-established industry players like Novartis and Gilead Sciences have made their CAR-T therapies accessible in some Asian countries, with Novartis even establishing cell therapy manufacturing sites in Japan in 2020.
Interestingly, a recent paper in the Blood Cell Therapy journal highlighted that Asia has been driving 70% of global economic growth in the past two years, projecting a 40% compound annual growth rate for CAR-T adoption in Asia.
Driving this wave are companies like Hebei Senlang Biotechnology and Chongqin Precision Biotech, both based in China, leading with 34 and 32 adoptive cell therapy trials, respectively.
Looking ahead, APAC is expected to maintain its leading role in the global cell therapy landscape, with a projected 40% compound annual growth rate for CAR-T adoption. The region's economic expansion and focus on innovation position it as a critical player in advancing cancer treatments and other therapeutic areas through adoptive cell therapies. However, challenges such as complex regulatory frameworks and supply chain issues remain, necessitating ongoing efforts toward regulatory harmonization and infrastructure development.
The conference, held in London, encompassed a wide array of topics, ranging from the UK's clinical trial landscape to the integration of AI in clinical trials, underscoring the rapid progress of the APAC region in the realm of adoptive cell therapies.
Key Takeaways
- APAC region leads in adoptive cell therapy clinical trials, with 12 times more single-country trials than Europe.
- There are 1,023 single-country adoptive cell therapy studies in APAC versus 476 in North America.
- Major adoptive cell therapies include Novartis’ Kymriah and Gilead Sciences’ Yescarta, available in some Asian countries.
- Asia has seen a 40% compound annual growth rate for CAR-T adoption, driven by economic growth.
- Top industry sponsors in adoptive cell therapy are Hebei Senlang Biotechnology and Chongqin Precision Biotech.
Analysis
The APAC region's dominance in adoptive cell therapy trials, propelled by economic growth and strategic investments, significantly influences global pharmaceutical giants like Novartis and Gilead Sciences, elevating their presence in the Asian market. This surge is predominantly led by Chinese firms Hebei Senlang Biotechnology and Chongqin Precision Biotech, signifying a notable shift in industry leadership. Immediate benefits encompass accelerated drug development and regulatory approvals in Asia, while long-term ramifications extend to potential reorientation of the global market and intensified competition in cell therapy innovation.
Did You Know?
- Adoptive Cell Therapy (ACT):
- It is a form of immunotherapy where cells are extracted from a patient's immune system, modified externally, and then reintroduced to combat diseases, particularly cancer, thereby enhancing the immune system's ability to recognize and eliminate cancer cells.
- CAR-T Cell Therapies:
- This type of adoptive cell therapy involves genetically modifying T-cells to express a chimeric antigen receptor (CAR) targeting specific proteins on cancer cells, enhancing the immune response against cancer.
- Compound Annual Growth Rate (CAGR):
- This measure calculates the average annual growth rate of an investment or business metric over a specified period, indicating a substantial and consistent expansion in the use of this therapy over time, as observed in CAR-T adoption in Asia, reflecting significant and consistent growth.